Home > Healthcare & Medical Devices > U.S. Intrauterine Devices Market

U.S. Intrauterine Devices Market Size By Product (Copper IUD, Hormonal IUD), By Age Group (15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45+), Industry Analysis Report, Zonal Outlook (East North Central (Illinois, Indiana, Michigan, Ohio, Wisconsin), West South Central (Arkansas, Louisiana, Oklahoma, Texas), South Atlantic (Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Washington, D.C.), North East (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, Pennsylvania), East South Central (Alabama, Kentucky, Mississippi, Tennessee), West North Central (Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota), Pacific Central (Alaska, California, Hawaii, Oregon, Washington), Mountain States (Arizona, Colorado, Utah, Nevada, New Mexico, Idaho, Montana, Wyoming)), Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2030

  • Report ID: GMI2895
  • Published Date: Jun 2022
  • Report Format: PDF

Industry Overview

U.S. Intrauterine Devices Market size surpassed USD 1.2 billion in 2021 and is estimated to witness over 10.5% CAGR between 2022 and 2030. Major factors driving the market growth include the favorable regulatory scenario, technological advancements, and implementation of favorable initiatives by the U.S. government. The ongoing advancements, innovations, and the integration of advanced technologies for enhancing the patient experience are anticipated to propel the market revenue.

Get more details on this report - Request Free Sample PDF

Intrauterine technology has been constantly evolving with an increased range of applications in birth control. The smaller frameless copper and levonorgestrel-releasing devices are increasing the preference for these devices among adolescent women. Market players are focusing to use new state-of-the-art technologies that enable them to develop strong and reliable devices. The rising contribution of such variables is set to prove beneficial for the U.S. market growth.

Intrauterine devices (IUD), also known as intrauterine contraceptive devices are employed for birth control that prevents pregnancy by stopping sperm from reaching and fertilizing eggs. It is a small and flexible contraceptive T-shaped device that can be inserted quickly & easily inside the uterus and physically prevent the implantation of fertilized ova. The 2 types of IUDs available are copper intrauterine devices and hormonal intrauterine devices.

However, adverse health issues comprising an infection of the uterus associated with the use of intrauterine devices may negatively impact the industry expansion. Bleeding and pain or discomfort are the key factors owing those women have an intrauterine device removed, accounting for over half of all removals before the usual replacement time. Few patients also experience other side effects after the IUD is placed such as cramps, irregular periods, spotting between periods, heavier periods with stronger cramping, etc. The pelvic inflammatory disease (PID) caused due to infection is one of the major disadvantages of intrauterine devices.

The recent outbreak of COVID-19 has negatively impacted the U.S. intrauterine devices market revenue. The revised standard operating protocols, and incorporation of social distancing norms have hindered the daily operations of several healthcare services, including common gynecologic procedures. The majority of the obstetrics and gynecological settings suspended or postponed the routine services and only catered to the emergency requirements. During the lockdown and travel restrictions, the published data indicate that the adoption of IUDs was impacted by the pandemic unfavorably in the gynecology hospitals & clinics. Further, as per the International Journal of Gynecology & Obstetrics, the supply chain disruptions had resulted in a stockout of several contraceptive methods comprising intrauterine devices across several zones in the country.

However, in 2021, as the number of COVID-19 affected patients reduced in several zones in the U.S., the gynecology hospitals & clinics resumed providing services including IUDs and steadily restoring the procedural volume to the pre-pandemic level. These factors are helping to uplift the market growth. Similarly, the technological developments, incorporation of telemedicine, and favorable initiatives have promoted the acceptance of intrauterine devices.  Thus, the COVID-19 pandemic has slightly affected the U.S. intrauterine devices market in the shorter run; however, the declining COVID-19 infection rates & patients and rising product adoption are set to facilitate the market expansion in the coming years.

Increasing inclination towards planned delayed pregnancy is expected to fuel the market statistics

Growing inclination towards planned delayed pregnancy in the U.S. is projected to promote the market growth. The adoption of novel strategies by the U.S. government to promote access to sexual & reproductive health services and products is expected to upsurge the inclination towards planned delayed pregnancy. The intrauterine devices are effective for 3 - 10 years and are around 99% efficient at preventing pregnancy. This variable has proven to be significant in increasing their adoption in planned delayed pregnancy. The rising adolescent female population across the country needs easy access to and use of contraceptives that include intrauterine devices to avoid problems such as unsafe abortions, unwanted pregnancy, etc. This is further contributing to the significant product adoption to prevent pregnancy. Furthermore, given the extensive implications of unintended pregnancies, the market opportunities for IUDs are anticipated to experience an upsurge in the coming years.

Growing demand for hormonal intrauterine devices is projected to propel the market forecasts

Get more details on this report - Request Free Sample PDF

Based on product, the market is segmented as copper IUD and hormonal IUD. The hormonal IUD segment was valued at USD 985 million in 2021. This is attributable to the several advantages and health benefits offered by hormonal intrauterine devices. These IUDs are one of the most efficient birth control methods that have proven to be effective around 99% in avoiding pregnancy. It aids in long-term contraception, low pelvic infection risk, less menstrual flow, and painless menstrual cycles among others. These hormonal IUDs are recommended by healthcare professionals due to their several health benefits and better patient outcomes. Hormonal IUDs are considered to be highly safe owing to their non-contraceptive benefits and can be used by patients having heavy menstrual bleeding, endometriosis, anemia, fibroids, etc. Hormonal IUDs prevent pregnancies by thickening the mucus in the cervix as well as thins the lining of the uterus that partially suppresses ovulation. Therefore, the several advantages and health benefits offered by hormonal IUD are expected to propel the demand for hormonal IUDs and surge the market revenue in the forthcoming period.

Rising use of intrauterine devices among 25-29 age group women is anticipated to drive the market statistics

Get more details on this report - Request Free Sample PDF

Based on age group, the market is segmented as 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, and 45+. The 25-29 age group segment was valued at around USD 259 million in 2021. This considerable market share is primarily owing to the rising awareness among 25-29 age group females regarding various IUD applications & consequences of unintended pregnancy, growing inclination towards planned delayed pregnancy, etc. Easy access to obstetricians and gynecologists that provide IUDs in their practice to the women population for the prevention of unwanted abortions and pregnancies is expected to drive product adoption among this age group.

As per the Guttmacher Institute studies, the percentage of unintended pregnancies is considerable in the age group of 25-29 years. The widespread IUD applications coupled with novel technological innovations contribute to effective contraception and fewer side effects, thereby augmenting product adoption in the prevention of unwanted abortions and pregnancies. As a result, the demand for IUDs witnessed a huge surge and is anticipated to follow the same trend in the coming years.

Favorable government initiatives for the prevention of unwanted abortions and pregnancies is expected to stimulate the overall business landscape

Get more details on this report - Request Free Sample PDF

South Atlantic zone dominated the U.S. intrauterine devices market and is anticipated to reach more than USD 609 million by 2030. This significant market share is attributed to several factors such as the presence of major industry players, an upsurge in the demand for IUDs, awareness of novel contraceptive devices comprising IUDs, etc. Several family planning efforts are taken by the government and non-government organizations including the increasing access to intrauterine contraceptive device for the prevention of unwanted abortions and pregnancies in the recent years is set to fuel the product demand in the South Atlantic zone. As per the contraceptive use report, in 2017-2019, around 69% of female family planning users were using some form of contraception in Florida.

Moreover, additional benefits offered by intrauterine devices such as long-term prevention of pregnancy, fewer side effects on fertility, less painful periods, and an effective form of contraception among others have increased the product adoption.

Business growth strategies implemented by major market players will amplify the industry landscape

The market players operating in the U.S. intrauterine devices industry are Bayer AG, CooperSurgical Inc. (CooperCompanies) and Allergan (AbbVie Inc.). Major market players are adopting strategic formulations such as forward integration, new product development, geographical expansion, and research collaborations to garner maximum industry share and promote company growth. These prominent market players are adopting various organic as well as inorganic growth strategies to obtain competitive advantage and strengthen their market position.

Recent industry developments:

  • In October 2019, Allergan plc announced the U.S. FDA approval for Medicines360's supplemental New Drug Application (sNDA) for LILETTA (levonorgestrel-releasing intrauterine system) 52 mg. This application was intended to extend the duration of preventing pregnancy for up to 6 years. This approval helped the company to increase its customer base and enhance its industry revenue.
  • In November 2017, Cooper Companies announced the acquisition of PARAGARD Intrauterine Device (IUD) from Teva Pharmaceutical Industries Ltd. It is a T-shaped copper intrauterine device that continuously release copper into the uterus that helps prevent fertilization. This strategic move helped the company in strengthening company’s position in the market.

U.S. intrauterine devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2030, for the following segments:

By product

  • Copper IUD
  • Hormonal IUD

By Age Group

  • 15-19
  • 20-24
  • 25-29
  • 30-34
  • 35-39
  • 40-44
  • 45+

The above information is provided for the following zones:

  • East North Central
    • Illinois
    • Indiana
    • Michigan
    • Ohio
    • Wisconsin
  • West South Central
    • Arkansas
    • Louisiana
    • Oklahoma
    • Texas
  • South Atlantic
    • Delaware
    • Florida
    • Georgia
    • Maryland
    • North Carolina
    • South Carolina
    • Virginia
    • West Virginia
    • Washington, D.C.
  • North East
    • Connecticut
    • Maine
    • Massachusetts
    • New Hampshire
    • Rhode Island
    • Vermont
    • New Jersey
    • New York
    • Pennsylvania
  • East South Central
    • Alabama
    • Kentucky
    • Mississippi
    • Tennessee
  • West North Central
    • Iowa
    • Kansas
    • Minnesota
    • Missouri
    • Nebraska
    • North Dakota
    • South Dakota
  • Pacific Central
    • Alaska
    • California
    • Hawaii
    • Oregon
    • Washington
  • Mountain States
    • Arizona
    • Colorado
    • Utah
    • Nevada
    • New Mexico
    • Idaho
    • Montana
    • Wyoming


Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

The global intrauterine devices industry in the U.S. generated a revenue of over USD 1.2 billion in 2021 and is poised to record a 10.5% CAGR between 2022-2030 owing to rising technological advancements for improving patient experience and favorable regulatory scenario.
The regional hormonal intrauterine devices (IUD) market share had crossed USD 985 million in 2021 and will expand with benefits like long-term contraception, less menstrual flow, low pelvic infection risk, and painless menstrual cycles.
The IUD market revenue in the U.S. from the 25-29 age group segment exceeded USD 259 million in 2021 and will rise with the increasing inclination towards planned delayed pregnancy.
In the U.S., South Atlantic zone intrauterine devices industry size is likely to cross USD 609 million by 2030 due to the strong presence of major industry players, and the surging awareness regarding novel contraceptive devices in the region.

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2021
  • Companies covered: 3
  • Tables & Figures: 295
  • Countries covered: 1
  • Pages: 207
  • Upcoming Report: Details can be customized to meet your information and data needs. Feel free to share your detailed research requirements via this form.

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount